Kyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics will participate in three September 2026 healthcare investor conferences, with live webcasts and 90-day replays for investors.
Rhea-AI Summary
Kyverna Therapeutics (KYTX)/b) announced that management will present at three September 2026 investor healthcare conferences, including Wells Fargo, Morgan Stanley and H.C. Wainwright, via fireside chats and investor meetings.Live webcasts and 90-day archived replays will be available in the Investors section of the company website.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:
2026 Wells Fargo Healthcare Conference
Format: Fireside chat and investor meetings
Date: Wednesday, September 9th, 2026
Time: 4:30 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside chat and investor meetings
Date: Monday, September 14th, 2026
Time: 4:05 p.m. ET
H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside chat and investor meetings
Date: Tuesday, September 15th, 2026
Time: 11:30 a.m. ET
Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. Archived replays of all events will be available on the website for approximately 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, as well as next generation innovations to expand patient access and evaluate future indications. For more information, please visit https://kyvernatx.com.
Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
FAQ
When will Kyverna Therapeutics (KYTX) present at the 2026 Wells Fargo Healthcare Conference?
Kyverna Therapeutics is scheduled to present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. ET, in a fireside chat format with additional investor meetings.
What is the date and time of Kyverna Therapeutics (KYTX) presentation at the Morgan Stanley 24th Annual Global Healthcare Conference?
Kyverna Therapeutics plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET, through a fireside chat and related investor meetings.
When is Kyverna Therapeutics (KYTX) presenting at the H.C. Wainwright 28th Annual Global Investment Conference?
The company intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11:30 a.m. ET, in a fireside chat format with investor meetings.
How can investors access the Kyverna Therapeutics (KYTX) webcasts for the September 2026 conferences?
Live webcasts of Kyverna Therapeutics’ September 2026 conference presentations may be accessed via the Investors section of its website at ir.kyvernatx.com. Archived replays of all events will be available for approximately 90 days following each conference.